New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2014
07:15 EDTTBIOTransgenomic board approves reverse stock split ratio
Transgenomic, announced that it has filed an application for listing its common shares on the NASDAQ. The company's proposed listing on the NASDAQ is subject to review by NASDAQ and dependent upon the company meeting all relevant quantitative and qualitative listing criteria of NASDAQ. The company believes it currently meets all of NASDAQ's eligibility requirements with the exception of the minimum bid price requirement, which will be addressed by a reverse split of the company’s common stock. In addition Transgenomic also announced that its board has approved a 1-for-12 reverse split of its issued and outstanding shares of common stock, with a planned effective date of January 27. After giving effect to the reverse stock split, every 12 shares of the company's issued and outstanding common stock will automatically be combined into one share of the company's issued and outstanding common stock. After the reverse split, the number of shares outstanding will be reduced from approximately 88.3M shares to approximately 7.4M shares. In connection with the reverse split, stockholders will not receive fractional post-reverse stock split shares. Instead, holders will receive cash in lieu of fractional shares.
News For TBIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
07:11 EDTTBIOTransgenomic launches ICE-COLD PCR service in biomarket identification business
Transgenomic announced that its groundbreaking Multiplexed ICE COLD PCR technology is now available to pharmaceutical and biotechnology customers of the company’s Biomarker Identification business unit. MX-ICP is an ultra-high sensitivity DNA amplification technology that allows the detection of multiple mutations in multiple genes from any sample, either from a tumor biopsy or from liquids such as blood or urine. MX-ICP is validated and available for use on all sequencing platforms.
April 15, 2015
16:10 EDTTBIOTransgenomic reports Q4 EPS (77c), one estimate (56c)
Reports Q4 revenue $7.7M, one estimate $6.11M.
08:26 EDTTBIOTransgenomic to hold a business news update conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use